

## Index

- 510(k) 196
  - submission 201
  - submission, types of 204
- Abbreviated NDA (ANDA) 188
- accelerated approval 194
- active pharmaceutical ingredient (API) 130, 237, 240
- Ambulatory Payment Classifications (APC) 288
- American Medical Academy (AMA) 283
- American Society for Testing of Materials (ASTM) 235
- analyte-specific reagents (ASR) 9, 15, 23, 212
- animal models 21
- Animal Welfare Act 120 Box 5, 121
- antisense 7
- barrier to entry, industry competition 13, 14, 15
- Bayh–Dole Act 86
- bioinformatics 7
- biologic, biotech drug, or large molecule drug 4, 7, 14, 20, 25, 132, 237
  - biogenerics 188
  - FDA definition 179
  - manufacture 238
- biomarker discovery 141
- biomarker validation 142
- bioreactor 4
  - bioreactor tanks for manufacturing 237
- bioremediation 5 Box 2
- biosafety 169
- biosimilars 188
- biotechnology 2, 4
- biotechnology industry 4, 7, 14, 21
- budget, for project 160
- build or buy decision 166, 243, 244, 250, 251
  - outsourcing product development 166
- business model 21, 47, 97, 108, 166, 216, 303
  - horizontal business model 100
  - IP management and commercialization 95
  - vertical 99
- business need 70
- business plan 36
- buyer power 13, 14
  - device industry 15
  - diagnostics 15
  - novel medical device 18
- capital expenditures 161
- cellular, tissue, and gene therapies 6, 17, 219
- Center for Biologics Evaluation and Research (CBER) 174
- Center for Devices and Radiological Health (CDRH) 175
- Center for Drug Evaluation and Research (CDER) 175
- Centers for Medicare and Medicaid Services (CMS) 3, 3, 212, 265, 290
- Centers of Disease Control (CDC) 212
- chemistry, manufacturing, and controls (CMC) 183
- claim forms, reimbursement 297
- classification, of medical devices 145, 198
  - database at the FDA website 198
- clean room 236
- clinical diagnostics or clinical chemistry 9, 214, 274
- clinical effectiveness data 302
- clinical endpoints 123
  - clinical endpoints, device 126
- Clinical Laboratory Improvement Amendments (CLIA) Act of 1998 208, 212
- clinical outcomes 111, 292
- clinical research organizations (CROs) 100
- clinical studies 21, 23, 132
  - clinical studies for in vitro diagnostic (IVD) devices 143
  - clinical study, control groups 153
  - study design for medical devices 151
  - study design for drugs 135
  - study design for diagnostics 143
- double-blind randomized trial 137, 150
- endpoint 123
  - endpoint for drugs 125 Box 4.7
  - endpoints for devices 126 Box 4.8
- Phases I, II, III, IV 21, 134, 139
- placebo control 135
- protocol 184

- randomized 137
- reimbursement influence on trial design 306
- sample size 143
- statistical power 143
- strength of trial design 281
  - historical control, devices 153
  - study design considerations 132
    - in foreign countries section 5.3.5
- clusters, biomedical industry 10, 11
- Code of Federal Regulation (CFR) 168
- co-development of diagnostics and drugs 142, 216
- coding (reimbursement related) 275, 282
- combination products 2, 217
  - example 92
    - stage gate development plan, example 119
- commodity product, device 8, 45
- competition 37, 50, 54, 57, 60
- competitive advantage 13, 14
- consumer (see customer)
- contract manufacturer organization (CMO) 21, 88, 251
- Contract Research Organization (CRO) 166
- contracted research 161
- control processes 230
- convergence of technologies 29, 30
- copyrights 64, 84
- cost
  - burden of healthcare 46
  - cost considerations and health economics 278
  - cost of developing diagnostic test 140
  - cost of drug development 21
  - cost of goods 243
  - cost of healthcare products and services 269
  - cost of the product 287
  - cost of treatments 49, 53
  - cost to get a patent 68
- cost-effectiveness (see economics)
- coverage 275
- CPT codes (see also HCPCS codes) 282, 288, 289, 313
  - new code 283
  - temporary code 294, 301
- critical path, FDA 177
  - Critical Path Opportunities List, FDA 177
- crossover controls, clinical study 150, 153
- cross-walking, diagnostic reimbursement 302
- current good clinical practice (cGCP)
  - guidelines 132
- current good laboratory practices (cGLP)
  - 131, 182
- current good manufacturing practices (cGMP)
  - 153, 228, 229
- customer 1, 15, 47, 50, 53
  - needs 146
- DEA – Drug Enforcement Agency 169
- demographics, population 45, 269
- description and specifications section, patents 71
- design
  - formal review 155, 246
- design controls, device development 146, 203, 231
- design for assembly 247
- design for manufacturability 150, 228, 247
- design for six sigma 148
- design history file (DHF) 154, 203
- design lock 120
- design patents, see also patents, design 66
- design-related defects 231
- device 2, 197
  - design inputs for device 146, 147, 205
  - device design 23, 145, 146
  - device development 144
  - industry 15, 57
  - primary mode of action 197
  - product design specifications (PDS)
    - document 146
  - reason for failure 110
  - reimbursement 273, 299
  - special controls 196, 201
  - packaging 246
  - sterilization 246
- device history record (DHR) 204
- device innovator companies 98
- device master record (DMR) 204, 248
- diagnosis related groups (DRG) 288, 297
- Diagnostic Device Evaluation and Safety, Office of In Vitro (OIVD) 207
- diagnostics 45, 51
  - diagnostic assay 38
  - diagnostic test development 111, 140
  - diagnostics development process 138
  - diagnostics industry 15, 24
  - diagnostics industry value chain 23
  - diagnostics market 9
  - diagnostics products that fail 110
  - diagnostics regulatory pathways 207
  - market 49, 55
  - reference labs 10, 16
- direct-to-consumer advertising 307
- disclosure, intellectual property 65
- discovery-driven planning, product development 116
- distribution 21
  - distribution channels 16
  - distributors 270
- doctrine of equivalents, patent infringement 79
- drug 4, 20, 179
  - development technology trends 24
  - drug clinical study designs, Box 4.13 135
  - drug pricing 271
  - drug targets 128

- drug (cont.)
  - global sales 7
  - reasons for failure 109
  - targetted 27
- drug master file (DMF) 138, 187
- drug price
  - wholesale acquisition cost (WAC) 285
  - average manufacturer price (AMP) 285
  - average sales price (ASP) 284, 285
  - average wholesale price (AWP) 284, 285
- drug target 20, 25
  - target discovery and validation 124, 139
  - validation 128
- due diligence on patents 88
- economic 292
  - cost-effectiveness 277, 278, 281
  - economic analysis 280
  - economic benefit 50
  - economic data 298
  - economics 36
  - health economics 278
  - healthcare economics 279
  - pharmacoeconomics 280, 293
  - value of a patent 64
- economic development 21, 49, 87
- end user (see customer)
- endpoints for drug studies 125
- entrepreneurs 21, 36
- environmental applications 5
- ethical requirements 120
- excipients 130, 237
- exclusive license (see license)
- exempt devices 201
- failure
  - early 110, 114
  - example in device development 113 Box 4.2
  - mode analysis, product development 156
- failure rate 21
- fast track process, FDA and drugs 192
- FDA
  - communication with CMS 277
  - FDA formally arranged meetings 185
  - FDA informal meetings 200
  - FDA Modernization Act of 1997, 193
  - label and marketing 57
  - product development protocol (PDP) 199
  - products not regulated by 175
  - regulatory delays and inconsistency 46
  - substantially equivalent (SE) 196, 199, 204, 211
  - clearance of 510(k) 199
  - priority review 194
- feasibility testing 145, 152, 155
  - for IVDs 23
- fee-for-service payment 267
- financial management 99
- financing 86
- first to file, patent 74
- first to invent, patent 74
- focus group (market research) 38, 39
- formulary 4, 272
  - closed 21
  - drug not covered 284
  - formulary placement 296
  - open 273
- formulation, drug 130, 137
- freedom to operate 80, 81
- full-time equivalent (FTE) 160
- Gantt charts and critical path 156
- gap-fill, reimbursement of diagnostics 302
- gene therapy 6, 7, 25
- generic drugs 14, 25, 46, 239
- genetically engineered 25
- guidance documents, from FDA 196
- Hatch Waxman Act 1984 195
- hazardous waste disposal 169
- HCPCS (see CPT codes)
- hits (drug development) 129, 139
- house of quality 108, 147
- human factors engineering 149
- Humanitarian Device Exemption (HDE) 207
- IACUC 120
- ICD-9 282, 283, 296
- in silico biology 25
- in vivo diagnostics 9
- incidence and prevalence 37, 40
- IND (Investigational New Drug Application)
  - 131, 183
  - research vs. commercial 184
- indication 53, 57, 108, 123, 146, 197
  - indication expansion 301
- informed consent form 121, 122
- injunction 82
- innovation 65, 97
  - devices 8
  - innovator diagnostics companies 98
- Inpatient Payment System (IPPS) 288, 297
- Institutional Animal Care and Use Committee (IACUC) 121
- Institutional Review Board (IRB) 121, 184
- intellectual property 3, 63
  - commercialization 85
  - management of 50, 99
  - rights 12
- interference proceedings (patents and USPTO)
  - 74, 75
- International Conference for Harmonization (ICH) 179, 229
- International Organization for Standardization (ISO) 228, 235

- invention date 75
- inventor 64, 71
- investigator's brochure, clinical trials 184
- investment decision 45, 86, 113
- IVD 9, 27, 207, 247
  - IVD industry 46
  - IVD product characteristics 248
  - IVD tests 16, 23
  - Multivariate Index Assays 210
  - technology platform 16, 23, 140
- key opinion leaders 306
- label, product 123
  - indications 151
- lab-on-a-chip 27
- labor laws 169
- Laboratory Fee Schedule 289, 302
- laws 2, 168, 173
- laws and regulations 45, 168, 173
- lead user groups (thought leaders) 39
- lead, drug development 129
  - lead identification and optimization 129, 130, 139
- learning plan approach 117
- license
  - co-exclusive 92
  - exclusive 90, 91
  - field of use 92
  - financial terms 90
  - grant of rights 89, 91
  - milestone payments 93
  - non-exclusive 90
  - partially exclusive 90
  - terms of license agreements 86, 88, 95
  - sublicense 91
- license royalty 86, 87, 93
  - reasonable royalty rate 94
  - royalty anti-stacking provisions 95
- licensee 86, 96
- licensor 89, 96
- literal infringement 79
- local coverage decision (LCD) 277
- Madrid Agreement and Protocol 84
- management in a matrix structure 159
- manufacturers, manufacturing 2, 23, 153
  - manufacturing cost 245
  - manufacturing plans 243
  - manufacturing process 251
  - manufacturing process validation 230, 240
  - manufacturing regulations 230
  - manufacturing technologies 230
- market acceptance, physicians 47
- market adoption diagnostic nucleic acid testing 16
  - market context 40, 47, 48
    - market need 36, 37, 49, 53
    - product intervention 50
    - referral chain 47
  - market exclusivity 195
  - market research
    - influence on product development 108, 124, 146
    - influence on reimbursement 244
    - survey methods 39
    - survey response rates 39
    - voice of the customer (VOC) 147
  - market segment 37
    - by geography 41
    - indication related to 56
  - market size
    - market segmentation 37, 41, 56, 60
    - market share projections 43
  - marketing, four Ps of marketing 305
  - master files, FDA 204
  - Materials Safety Data Sheets (MSDS) 169
  - Medicaid 269
  - medical device 2, 13, 23
    - industry 8
  - medical device design 60
  - Medical Device User Fee and Modernization Act of 2002 (MDUFMA) 177
  - Medical Science Liaison (MSL) 309
  - medical specialty group 294
  - Medicare 45, 266, 286
    - Medicare coverage 267
    - Medicare lab fee schedule 274
    - Medicare Modernization Act of 2005, 45
      - Part A Hospital Insurance 268
      - Part B Medical Insurance 268
      - Part C 268
      - Part D Prescription Drug Coverage 269, 293
  - milestone, development 20, 109, 116
  - molecular diagnostics (nucleic acid tests or genetic testing 45, 209, 210, 212
    - ASRs 212
    - CLIA regulated 210
    - competitiveness 16
    - molecular imaging 9
    - nucleic acid testing (NAT) 10, 27
    - reimbursement challenges 303
    - segment of IVD market 10
    - stratified medicine 27
    - technology trends 27
  - monoclonal antibody (mAb) 6, 174, 183
  - multi-disciplinary 27, 104
    - research 31
    - teams 105, 158
- NAICS (North American Industrial Classification System) 11, 33

- NAICS or SIC (Standard Industrial Classification codes) 11
- nanotechnology, nanoscale 28, 30
- national coverage decision (NCD) 277
- National Drug Codes (NDC) 283
- national health care systems 46, 304
- NDA, new drug application 185
- negligence 310
- net present value (NPV) 162
- new product development (NPD) 19, 104
- NIH 3
- NIH roadmap 45
- nucleic acids 4, 6
- Office of Cellular, Tissue, and Gene Therapies 174
- Office of Combination Products 217
- Office of In vitro Diagnostics (OIVD) 176
- oligonucleotide 4
- Orange Book 188, 195
- Orphan Drug Act of 1983 46, 196
- Outpatient Payment System (OPPS) 288, 298
- Outsourcing (see build or buy decision)
- over-the-counter (OTC) drugs 188
- patent
- prior art 70, 74
- patents 37, 46, 64
- assignee 71
  - claims, patent 65
  - composition of matter 65
  - considerations before filing 69
  - costs 78
  - infringement 75, 78, 79, 94
  - national phase, patent application 76, 78
  - non-provisional patent application 73, 77
  - Patent Cooperation Treaty (PCT) 74, 76, 77
  - patentability 68
  - plant 66
  - provisional patents 73, 76
  - specification 65
  - term 68
  - term extension 68
  - utility 65
  - validity 68
  - priority date 73
- patient compliance 47
- payer 265, 266
- cost considerations and health economics 278
  - educating the payers 301 Box 6, 307
  - patient 1
- payment 275, 284
- diagnostics 302
  - for drugs to pharmacy 284
  - for physician administered products 284, 286
  - government policy 289
  - Physician's fee 288
  - payment (also see reimbursement) devices 297
- personalized medicine (see also stratified medicine) 29, 215
- pharmaceutical industry 2, 4, 7, 25
- pharmacogenetic 215
- pharmacogenomic (PGx) 215
- pharmacokinetics and bioavailability 187
- pharmacology 182, 185, 186
- pharmacy benefit manager (PBM) 1, 271
- Physician Fee Schedule 288, 298, 300, 301
- pilot production
- devices and diagnostics 246
  - for bulk drugs 242
- PMA 196
- PMA submission 201, 206
- point of care (POC) 111
- policy, government 2, 3
- Porter's five forces 11, 13, 15, 18
- post-market clinical studies (Phase IV) 189
- pre-approval inspection 228, 240, 245
- pre-clinical research 20, 181
- drugs 183
  - toxicity 182
- predicate device 199, 204, 205
- Pre-IND meeting 185
- Prescription Drug User Fee Act (PDUFA) 176
- prevalence (see incidence and prevalence)
- price controls 3
- price sensitivity 46, 49
- private insurers or payers 269, 293
- product characteristics 36, 37, 38, 108, 119, 148
- product design specifications (PDS) document (see device)
- product development 19, 24, 36
- product development cycle 14
  - product life cycle 106, 108
  - project management tools 156
  - project manager 159
  - project proposal 106
  - project schedules 158
  - proof of concept 19
- product liability 309
- product recall 230, 311
- profit margins, profitability 8, 22, 37, 46
- proof of concept (see feasibility testing)
- prospective payment (see reimbursement) 267, 287
- prototype 19, 23, 38, 150
- provider (of healthcare services) 265, 267, 269
- purchase-influencers 53, 277, 284, 296
- group purchasing organizations 15, 270
- purchasing decision 1, 46, 270, 306
- Pharmacy and Therapeutics (P&T) Committee 272

- quality
  - QSR, failure to comply 249
  - quality assurance (QA) 229
  - quality control (QC) 229
  - Quality System Regulation (21 CFR Part 820) 199, 202, 233
  - quality system, drugs 254
- radical innovations 116
- recombinant DNA 25
- regenerative medicine 6
- regulated industry 290
- reimbursement (see also payment)
  - components 274
  - marketing 306
  - path for devices and physician-administered drugs 293
  - path for self-administered drugs (mostly pills) 302
  - pathway for in vitro diagnostics (IVD) 302
  - relative value for a physician's service 288
- reimbursement planning 265, 284, 291, 301
- reimbursement policies 269
- reliability testing 150, 228
- research tools 7
- risk-sharing 14
- safety versus efficacy 113
- sales 37, 307
- scale-up (manufacturing) 130, 141, 155, 227, 242, 245
- siRNA (short interfering RNA) 7, 25
- small molecule 4, 20, 25, 238, 242
- stakeholder analysis 164
- standard operating procedures (SOP) 203, 245
- standards 20
  - manufacturing 228, 233
- stem cells 25
- strategic planning 13, 106
- substitute products 11, 13, 14, 18
- suppliers 11, 13, 14, 15, 18
  - supplier power 14, 15
- supply chain 17
- target (see drug target)
- technology assessment 280, 313
- technology transfer
  - intellectual property 86
  - R&D to manufacturing 227, 243, 246
- tissue-engineered products 6, 17, 25, 27, 219
- toxicity testing 149
- toxicology 21, 182
- trade secret 64, 84
- trademarks 64, 82
- transitional pass-through CPT code 288, 298
- usage decision 270
- vaccines 4, 45, 183
- validation, analytical methods 141, 240
- valuation
  - NPV, project 162
- value
  - intellectual property 64, 85, 93, 94
- value chain 11, 21, 108
  - business model 166
  - diagnostics 24 (Figure 1.6)
  - segments of the 22
  - service companies 100
- value proposition 47, 50, 281, 291
- venture capital 45
- Veterans' Administration 266
- wholesalers 269